Diabetes Center, Zhejiang Provincial Key Laboratory of Pathophysiology, Institute of Biochemistry and Molecular Biology, School of Medicine, Ningbo University, Ningbo, China.
Autoimmunity. 2020 Jun;53(4):210-217. doi: 10.1080/08916934.2020.1735371. Epub 2020 Mar 4.
Chymase 1 (CMA1), a gene known to be expressed in mast cells (MCs), is largely linked to immunity. However, the relationship between CMA1 and prognosis of multiple tumours and tumour-infiltrating lymphocytes (TILs) remains elusive. The differential expressions of CMA1 in different tumours and their corresponding normal tissues were evaluated exploring Tumour Immune Estimation Resource (TIMER) and Oncomine database; the correlation within expression level of CMA1 and outcome of cancer patients was evaluated Kaplan-Meier plotter and Gene Expression Profiling Interactive Analysis (GEPIA) database; the correlation between CMA1 and tumour immune cell infiltration was further investigated by TIMER; additionally, the correlation between CMA1 and gene signature pattern of immune infiltration were checked using TIMER and GEPIA. There were significant differences in CMA1 expression levels between gastric cancer (GC) tissues and adjacent normal tissues. The high expression of CMA1 was closed related to poor overall survival (OS) and progression-free survival (PFS) in patients with GC (OS HR = 1.50, = .00015; PFS HR = 1.33, = .016). Especially, in GC patients at N1, N2 and N3 stages, high CMA1 expression was correlated with poor OS and PFS, but not with NO ( = .15, .09). The expression of CMA1 was positively associated with the levels of infiltrated CD4+, CD8+ T cells, neutrophils, macrophages, and dendritic cells (DCs) in GC. Whereas, CMA1 expression was considerably associated with various immune markers. CMA1 is a key gene whose expression level is significantly correlated with GC prognosis and infiltration levels of CD8+, CD4+ T cells, neutrophils, macrophages, and DCs in GC. In addition, the expression of CMA1 may be involved in regulating tumour-associated macrophages (TAMs), dendritic cells, exhausted T cells and regulatory T cells in GC. It suggests that CMA1 could be utilized as a prognostic marker and a sign of immune infiltration in GC.
糜酶 1(CMA1)是一种已知在肥大细胞(MCs)中表达的基因,主要与免疫有关。然而,CMA1 与多种肿瘤和肿瘤浸润淋巴细胞(TILs)的预后之间的关系仍不清楚。通过探索肿瘤免疫估计资源(TIMER)和 Oncomine 数据库评估了 CMA1 在不同肿瘤及其相应正常组织中的差异表达;通过 Kaplan-Meier plotter 和基因表达谱分析交互分析(GEPIA)数据库评估了 CMA1 表达水平与癌症患者预后之间的相关性;通过 TIMER 进一步研究了 CMA1 与肿瘤免疫细胞浸润的相关性;此外,通过 TIMER 和 GEPIA 检查了 CMA1 与免疫浸润基因特征模式的相关性。胃癌(GC)组织与相邻正常组织之间的 CMA1 表达水平存在显著差异。CMA1 的高表达与 GC 患者的总生存(OS)和无进展生存(PFS)不良密切相关(OS HR=1.50,P=0.00015;PFS HR=1.33,P=0.016)。特别是在 GC 患者的 N1、N2 和 N3 期,CMA1 高表达与 OS 和 PFS 不良相关,但与 NO 无关(P=0.15,P=0.09)。CMA1 的表达与 GC 中浸润的 CD4+、CD8+T 细胞、中性粒细胞、巨噬细胞和树突状细胞(DCs)水平呈正相关。然而,CMA1 表达与各种免疫标志物显著相关。CMA1 是一个关键基因,其表达水平与 GC 预后以及 GC 中 CD8+、CD4+T 细胞、中性粒细胞、巨噬细胞和 DCs 的浸润水平显著相关。此外,CMA1 的表达可能参与调节 GC 中的肿瘤相关巨噬细胞(TAMs)、树突状细胞、耗竭性 T 细胞和调节性 T 细胞。这表明 CMA1 可作为 GC 的预后标志物和免疫浸润标志物。